Canary Bio Passes DSMB Review for Global Phase 3 Clinical Trial in September

[Asia Economy Reporter Jang Hyowon] Canary Bio announced on the 26th that the global Phase 3 clinical trial of Oregovomab, conducted at 152 sites across 16 countries targeting ovarian cancer patients, has passed the review by the DSMB (Data Safety Monitoring Board).

This global Phase 3 clinical trial undergoes clinical data review every six months by the DSMB. The DSMB has the authority to halt the trial not only if serious safety issues arise but also if it determines that there is no efficacy.

Canary Bio received a recommendation to continue the trial at the DSMB meeting held on the 21st. The next DSMB review is scheduled for March 2023. Additionally, interim results are expected to be announced in the third quarter of next year.

Meanwhile, Oregovomab is a new drug that showed an increase in progression-free survival (PFS) to 42 months, which is 30 months longer compared to the existing standard treatment, in a Phase 2 clinical trial targeting ovarian cancer patients. The P-value for overall survival (OS) was 0.0043, and the P-value for progression-free survival (PFS) was 0.0027.